Nanjing Immunophage Biotech Co., Ltd
Clinical trials sponsored by Nanjing Immunophage Biotech Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug IPG1094 gets first human test in china Results expected Jan 2027 (estimated)
- New pill shows promise in early trial for Hard-to-Treat cancers Results expected Jul 2027 (estimated)
-
New pill aims to tame lupus kidney damage
Disease control CompletedThis early-stage trial tests a new daily pill, IPG11406, in 36 adults with lupus nephritis—a kidney complication of lupus. The study checks if the drug is safe and whether it can reduce protein in the urine and improve kidney function. It is too soon to know if it works, but the …
Phase 1/2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill hopes to fight Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental oral drug called IPG7236 in people with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, then expanding to see if the drug can control tumor growth. About 196 participant…
Phase 1/2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug IPG1094 takes first step in human safety trial
Knowledge-focused CompletedThis early-stage study tested a new oral drug called IPG1094 in 76 healthy adults aged 18 to 50. The main goal was to check the drug's safety and how the body processes it. Participants received either the drug or a placebo, and researchers monitored for side effects. This trial …
Phase 1 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New pill for gut disease passes first safety check in healthy volunteers
Knowledge-focused CompletedThis early-stage trial tested a new oral drug called IPG11406 in 66 healthy adults to see if it is safe and how the body processes it. The drug is designed to treat inflammatory bowel diseases like Crohn's disease and ulcerative colitis. Participants received either the drug or a…
Phase 1 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC